- Home
- Meet the Innovators
- IMMUNE WATCH
Platform DESIGN for rapid prediction of vaccine composition
ImmuneWatch is a spin-off of the University of Antwerp and the University Hospital Antwerp, based in Dunden. They develop innovative AI applications in the field of vaccinology and infectious diseases. With the support of the city of Antwerp, they are developing a new platform, DESIGN, that can make predictions about the best composition of new vaccines at an earlier stage (before clinical trials).
In addition, they plan to commercialise their existing platform DETECT. This platform allows researchers to gain unique insights into the response to a vaccine.Both service platforms are complementary.
ImmuneWatch will ensure that vaccine development will be faster and more (cost) efficient. This will further strengthen Antwerp in the field of vaccinology.
ImmuneWatch develops innovative applications in the field of vaccinology and infectious diseases based on bioinformatics and artificial intelligence. The company specialises in the prediction and monitoring of immune responses with a focus on T-cells.
ImmuneWatch offers commercial services to vaccine developers that provide new insights into vaccine function and efficacy based on the analysis of T-cell data. The company also invests in the continuous improvement of its technology platform (algorithms, immunoinformatics pipelines, expansion of the internal database) to enable the development of new products for applications in vaccinology and personalised medicine.
This project had two objectives:
-
to accelerate the commercialisation of the DETECT platform by focusing on business development and the establishment of (inter)national research collaborations. DETECT analyses samples from patients who have received a vaccine in a clinical trial and provides new and detailed insights into the immune response to the vaccine,
-
product development and market exploration for DESIGN by setting up end-user interviews and developing a minimal viable product (MVP). DESIGN allows the content of a vaccine to be improved at an early stage of development to increase the chances of success in the clinical phase.
